Immunocore Holdings plc (IMCR)

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore to present at upcoming investor conferences

Bank of America Corp DE Trims Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR

Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss

Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues

Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript

Immunocore Q2 Earnings Call Highlights

Immunocore reports second quarter financial results and provides a business update

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead

Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?

How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak